Vanidassane Ilavarasi, Sharma Aparna, Aggarwal Aditi, Gunasekar Sudhakar, Barwad Adarsh, Dhamija Ekta, Pandey Rambha, Deo Suryanarayana, Garg Rakesh, Rastogi Sameer
Department of Medical Oncology, IRCH, AIIMS, New Delhi, India.
Department of Radiation Oncology, Lok Nayak Hospital, New Delhi, India.
South Asian J Cancer. 2019 Jan-Mar;8(1):69-71. doi: 10.4103/sajc.sajc_229_18.
Head-and-neck soft-tissue sarcomas (HNSTS) are extremely rare and lack definite guidelines.
We retrospectively analyzed consecutive adult patients with HNSTS who presented to our sarcoma medical oncology clinic from January 2016 to October 2017.
There were a total of 30 patients. Unresectable localized disease was seen in 13 (43%) patients, metastatic disease 10 (34%) patients, while resectable disease in 7 (23%) patients only. Among unresectable localized disease, 3 (25%) patients could be converted to resectable disease after neoadjuvant therapy. Median follow period was 11 months. Progression-free survival was 19 months in patients with resectable disease and 6 months in patients with the unresectable/metastatic disease. Median OS was not reached.
Unresectable HNSTS has a poor outcome. Neoadjuvant therapy can be tried in selected cases for achieving respectability or for vital organ preservation until robust data are available. A multidisciplinary approach for local control is crucial in managing unresectable HNSTS.
头颈部软组织肉瘤（HNSTS）极为罕见，且缺乏明确的指导方针。
我们回顾性分析了2016年1月至2017年10月期间到我们肉瘤内科肿瘤门诊就诊的连续性成年HNSTS患者。
共有30例患者。13例（43%）患者为不可切除的局限性疾病，10例（34%）患者为转移性疾病，仅7例（23%）患者为可切除疾病。在不可切除的局限性疾病患者中，3例（25%）患者在新辅助治疗后可转变为可切除疾病。中位随访期为11个月。可切除疾病患者的无进展生存期为19个月，不可切除/转移性疾病患者为6个月。中位总生存期未达到。
不可切除的HNSTS预后较差。在有可靠数据之前，对于部分病例可尝试新辅助治疗以实现可切除性或保留重要器官。多学科局部控制方法对于管理不可切除的HNSTS至关重要。
